Fujifilm Kyowa Kirin biosimilars JV cues up adalimumab as first target
This article was originally published in Scrip
Executive Summary
Following the formal start of business operations at their new biosimilars joint venture, Fujifilm Kyowa Kirin Biologics, Fujifilm and Kyowa Hakko Kirin have revealed that its first target will be the anti-tumour necrosis factor antibody adalimumab.